cloral betaine: clinical use

Prescribing considerations

• Reserve for severe insomnia after behavioural and pharmacological therapies have failed.
• Adolescent use is restricted to suspected or confirmed neurodevelopmental disorder and requires specialist supervision.
• Assess misuse, dependence and withdrawal risks, particularly with a history of alcohol or substance dependence.
• Consider increased confusion, ataxia and falls risk in frail or older patients.
• Use caution with previous gastrointestinal inflammation or ulceration, mild-to-moderate hepatic or renal impairment, electrolyte disturbance, bradyarrhythmia or long-QT risk.

Contraindications and cautions

• Hypersensitivity to cloral betaine, chloral hydrate or an excipient.
• Severe hepatic impairment.
• Severe renal impairment or renal failure.
• Severe cardiac disease.
• Active gastritis, oesophagitis, gastric or duodenal ulceration, or gastrointestinal perforation.
• Susceptibility to acute porphyria attacks.
• Pregnancy and breastfeeding according to the selected product information.

Monitoring

• Sedation, respiratory depression, cognition, coordination and falls risk.
• Emerging tolerance, misuse, dependence or withdrawal symptoms.
• Renal, hepatic and gastrointestinal adverse effects where clinically indicated.
• ECG and electrolytes when cardiac or QT-prolongation risks are present.
• Prothrombin time when anticoagulant therapy is started, changed or withdrawn alongside chloral therapy.
• Interpret thyroid-function tests cautiously because chloral hydrate may interfere with results.

Clinical pharmacology

Cloral betaine dissociates to chloral hydrate and betaine. Chloral hydrate is rapidly absorbed and converted mainly to active trichloroethanol, producing central nervous system depression through proposed mechanisms including GABA-A potentiation.

Formulation and product differences

• The selected product is a film-coated tablet that provides cloral betaine as a precursor of chloral hydrate.
• The selected tablet products are listed as discontinued on eMC; confirm availability and alternatives locally.
• The formulation contains colourants and preservatives capable of causing allergic reactions in susceptible people.